Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders presents updated reviews on the chemistry, signaling, pre-clinical and clinical activities on the role of nitric oxide donors/inhibitors used alone and in combination with other therapeutic agents for the treatment of a variety of diseases. This book examines various studies related to the application of novel therapeutic NO (donors/inhibitors) compounds in the treatment of various cancers. These studies have been shown to exert significant therapeutic activities against various cancers and various inflammatory…mehr
Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders presents updated reviews on the chemistry, signaling, pre-clinical and clinical activities on the role of nitric oxide donors/inhibitors used alone and in combination with other therapeutic agents for the treatment of a variety of diseases. This book examines various studies related to the application of novel therapeutic NO (donors/inhibitors) compounds in the treatment of various cancers. These studies have been shown to exert significant therapeutic activities against various cancers and various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, allergies, and asthma, where no current effective therapies exist. Pathologies based on functional and structural vascular alterations are also taken into consideration.
Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students. Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Dr. Morbidelli's experience is within the molecular and biochemical pharmacology of angiogenesis and microcirculation and its biological application in diseases and cancer. Through of a plethora of in vitro and in vivo models, she has contributed to the characterization of the pro- and antiangiogenic activities of designed synthetic molecules and natural products and their potential applications in angiogenesis-dependent diseases of the cardiovascular system, ocular disorders, neurovascular diseases and cancer. She co-organized with Professor Bonavida the Fourth International Workshop on "Nitric Oxide in Cancer? held in Sevilla in March 13-14, 2015. The meeting addressed different topics such as NO, mutagenesis, carcinogenesis, tumor promotion and tumor growth; NO regulation of cell death pathways; NO and proliferation and epithelial-mesenchymal transition; Regulation of immune response by NO; Antitumoral activity of NO-based releasing strategies: pre-clinical studies; Antitumoral
activity of NO-based releasing strategies: clinical trials. Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
Inhaltsangabe
I. Applications of Nitric Oxide in Cancer1. Nitric Oxide-Releasing Engineered Nanoparticles: Tools for Overcoming Drug Resistance in Chemotherapy2. Reversal of Multiple Cancer Oncogenic Pleiotropic Properties by NO-modulating Therapies3. Antitumor Effect of a Metal Nonoate Through Angiogenesis Impairment4. Therapeutic Implications of the Nitric Oxide Pathway in the Angiogenesis of Tumors and Inflammatory-Related Disorders5. Nitric oxide and cancer: To inhibit or to induce iNOS - That is the Question?6. Arginine Metabolism Regulates Nitric Oxide Production in Melanoma Tumor Microenvironment to Provide Survival Advantage to Tumor Cells7. Cancer and Beyond: Discovery and Development of NO-releasing Therapeutics8. Nitric Oxide Scavenging-Based Therapies for Targeting Colorectal Cancer9. Therapeutic Aspects of Protein Denitrosylation10. Nitric Oxide-Releasing Functional Nanomaterials for Anticancer Therapy
II. Applications of Nitric Oxide in Inflammatory-Related Disorders11. The Role of Nitric Oxide on Vascular Dysfunction During Aging and Alzheimer's Disease12. Carbonic Anhydrase Inhibitor - NO Donor Hybrids and Their Pharmacologic Applications13. Understanding the Roles of Nitric Oxide During Sepsis, an Inflammatory Disorder14. Nanoporous Materials: New Generation of Nitric Oxide Donors
III. Abstracts (Presentations at Conference in Siena, October 4th-5th, 2018)A. Serum Nitric Oxide Metabolites and The Incidence of Metabolic Syndrome and Its Phenotypes: A Population-Based Prospective StudyB. Nitric Oxide (NO): A Multifaceted Target for Reversal of Cancer Cell Pleiotropic Properties by NO-modulating TherapiesC. Pharmacology of Hepatoselective Nitric Oxide - Donors in NAFLD in MiceD. New NO-Releasing Doxorubicins as Targeted Therapy Against Chemoresistance in Castration-resistant Prostate Cancer: In Vitro and In Vivo EvaluationsE. Anticancer Effect of a Novel H2S-Hybrid Molecule on Human Breast Adenocarcinoma (MFC-7) and Human Breast Epithelial (MCF-10A) Cell LinesF. Heme Oxygenase-1 In Duchenne Muscular Dystrophy: Interaction with Nitric Oxide Synthase Pathway in Satellite Cells DifferentiationG. In Vitro Assessment of NitDox Toxicity Towards VasculatureH. The Regulation of GSNOR Expression Discloses the Role of S-nitrosylation in Aging and DiseaseI. Effects of Long-term Nitrite Supplementation on Gene Expressions of GLUT2, GLUT4 and Glucokinase in Male Obese Type 2 Diabetic RatsJ. Nitric Oxide Re-Instates Doxorubicin Cytotoxic and Pro-Immunogenic Effects in Refractory Breast CancerK. Anti-Cancer Activities of Erucin a H2S-donor Isothiocyanate from Eruca Sativa Mill.: Is H2S the Real Player?L. Hydrogen Sulfide as a Signaling Molecule in The Cardiovascular System: Actions and Interactions with NOM. Nitric Oxide in Cancer Resistance to Cisplatin: Tumor Associated Macrophages as Key Players.N. Therapeutic Potential of Nitric Oxide Modulation in Ocular Diseases: A Focus on Novel NO-Releasing MoleculesO. Pro-Apoptotic Effects of S-Nitrosothiols O-Chloro and M-Chloro S-Nitroso-Aryl-Amides in Human Breast Cancer Cell LinesP. Light Guided Production of Nitric Oxide and Singlet Oxygen for the Multi-Modal Treatment of CancerQ. Potential for Chemoprevention with Nitric Oxide- and Hydrogen Sulfide-Releasing DrugsR. H2S Metabolism in Colon Cancer Cells Exposed to Hypoxia
I. Applications of Nitric Oxide in Cancer1. Nitric Oxide-Releasing Engineered Nanoparticles: Tools for Overcoming Drug Resistance in Chemotherapy2. Reversal of Multiple Cancer Oncogenic Pleiotropic Properties by NO-modulating Therapies3. Antitumor Effect of a Metal Nonoate Through Angiogenesis Impairment4. Therapeutic Implications of the Nitric Oxide Pathway in the Angiogenesis of Tumors and Inflammatory-Related Disorders5. Nitric oxide and cancer: To inhibit or to induce iNOS - That is the Question?6. Arginine Metabolism Regulates Nitric Oxide Production in Melanoma Tumor Microenvironment to Provide Survival Advantage to Tumor Cells7. Cancer and Beyond: Discovery and Development of NO-releasing Therapeutics8. Nitric Oxide Scavenging-Based Therapies for Targeting Colorectal Cancer9. Therapeutic Aspects of Protein Denitrosylation10. Nitric Oxide-Releasing Functional Nanomaterials for Anticancer Therapy
II. Applications of Nitric Oxide in Inflammatory-Related Disorders11. The Role of Nitric Oxide on Vascular Dysfunction During Aging and Alzheimer's Disease12. Carbonic Anhydrase Inhibitor - NO Donor Hybrids and Their Pharmacologic Applications13. Understanding the Roles of Nitric Oxide During Sepsis, an Inflammatory Disorder14. Nanoporous Materials: New Generation of Nitric Oxide Donors
III. Abstracts (Presentations at Conference in Siena, October 4th-5th, 2018)A. Serum Nitric Oxide Metabolites and The Incidence of Metabolic Syndrome and Its Phenotypes: A Population-Based Prospective StudyB. Nitric Oxide (NO): A Multifaceted Target for Reversal of Cancer Cell Pleiotropic Properties by NO-modulating TherapiesC. Pharmacology of Hepatoselective Nitric Oxide - Donors in NAFLD in MiceD. New NO-Releasing Doxorubicins as Targeted Therapy Against Chemoresistance in Castration-resistant Prostate Cancer: In Vitro and In Vivo EvaluationsE. Anticancer Effect of a Novel H2S-Hybrid Molecule on Human Breast Adenocarcinoma (MFC-7) and Human Breast Epithelial (MCF-10A) Cell LinesF. Heme Oxygenase-1 In Duchenne Muscular Dystrophy: Interaction with Nitric Oxide Synthase Pathway in Satellite Cells DifferentiationG. In Vitro Assessment of NitDox Toxicity Towards VasculatureH. The Regulation of GSNOR Expression Discloses the Role of S-nitrosylation in Aging and DiseaseI. Effects of Long-term Nitrite Supplementation on Gene Expressions of GLUT2, GLUT4 and Glucokinase in Male Obese Type 2 Diabetic RatsJ. Nitric Oxide Re-Instates Doxorubicin Cytotoxic and Pro-Immunogenic Effects in Refractory Breast CancerK. Anti-Cancer Activities of Erucin a H2S-donor Isothiocyanate from Eruca Sativa Mill.: Is H2S the Real Player?L. Hydrogen Sulfide as a Signaling Molecule in The Cardiovascular System: Actions and Interactions with NOM. Nitric Oxide in Cancer Resistance to Cisplatin: Tumor Associated Macrophages as Key Players.N. Therapeutic Potential of Nitric Oxide Modulation in Ocular Diseases: A Focus on Novel NO-Releasing MoleculesO. Pro-Apoptotic Effects of S-Nitrosothiols O-Chloro and M-Chloro S-Nitroso-Aryl-Amides in Human Breast Cancer Cell LinesP. Light Guided Production of Nitric Oxide and Singlet Oxygen for the Multi-Modal Treatment of CancerQ. Potential for Chemoprevention with Nitric Oxide- and Hydrogen Sulfide-Releasing DrugsR. H2S Metabolism in Colon Cancer Cells Exposed to Hypoxia
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
